bluebird bio Inc  

(Public, NASDAQ:BLUE)   Watch this stock  
Find more results for BLUE
+4.80 (2.33%)
Real-time:   10:23AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 206.75 - 210.65
52 week 73.95 - 222.03
Open 206.75
Vol / Avg. 44,122.00/948,001.00
Mkt cap 10.31B
P/E     -
Div/yield     -
EPS -7.01
Shares 49.03M
Beta 2.07
Inst. own 108%
Feb 21, 2018
Q4 2017 bluebird bio Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 14, 2018
bluebird bio Inc at Leerink Partners Global Healthcare Conference
Jan 9, 2018
bluebird bio Inc at JPMorgan Healthcare Conference Q&A Breakout Session
Jan 9, 2018
bluebird bio Inc at JPMorgan Healthcare Conference - Webcast
Dec 10, 2017
bluebird bio Inc ASH Investor and Analyst Webcast - Webcast
Nov 30, 2017
bluebird bio Inc at Barclays Gene Editing and Gene Therapy Summit
Nov 29, 2017
bluebird bio Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1021.98% -4281.19%
Operating margin -1007.11% -4351.42%
EBITD margin - -4193.83%
Return on average assets -22.08% -24.85%
Return on average equity -27.00% -30.64%
Employees 418 -
CDP Score - -


60 Binney St
CAMBRIDGE, MA 02142-1512
United States - Map
+1-339-4999300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Officers and directors

Daniel S. Lynch Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Nick Leschly President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Jeffrey T. Walsh Chief Financial Officer, Principal Financial Officer and Strategy Officer
Age: 51
Bio & Compensation  - Reuters
Susanna Gatti High Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Kory J. Wentworth Principal Accounting Officer, Vice President - Finance
Age: 39
Bio & Compensation  - Reuters
Philip D. Gregory Ph.D. Chief Scientific Officer
Age: 46
Bio & Compensation  - Reuters
David M. Davidson M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Jason F. Cole Esq. Chief Legal Officer, Secretary
Age: 44
Bio & Compensation  - Reuters
John O. Agwunobi M.D. Director
Age: 52
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. Director
Age: 54
Bio & Compensation  - Reuters